Prediabetes and CKD: does a causal relationship exist?
| datacite.rights | http://purl.org/coar/access_right/c_abf2 | |
| dc.contributor.author | Rico Fontalvo, Jorge | |
| dc.contributor.author | Soler, María José | |
| dc.contributor.author | Daza Arnedo, Rodrigo | |
| dc.contributor.author | Navarro-Blackaller, Guillermo | |
| dc.contributor.author | Medina-González, Ramón | |
| dc.contributor.author | Rodríguez Yánez, Tomas | |
| dc.contributor.author | Cardona-Blanco, Maria | |
| dc.contributor.author | Cabrales-Juan, Jose | |
| dc.contributor.author | Uparrela-Gulfo, Isabella | |
| dc.contributor.author | Chávez-Iñiguez, Jonathan S. | |
| dc.date.accessioned | 2024-06-24T14:44:11Z | |
| dc.date.available | 2024-06-24T14:44:11Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | The relationship between diabetes and the development of kidney complications is well known, but the understanding of prediabetes and insulin resistance with impaired kidney function has been scarcely assessed. Various factors could explain this phenomenon, from the lack of standardization in the definitions of prediabetes, to the erratic and inconsistent evidence in large-scale epidemiological and cohort studies. It seems that the pathophysiological pathway of prediabetes could be related to inflammation and neurohormonal hyperactivation, factors present even before the onset of diabetes, which might be the main drivers of glomerular hyperfiltration, albuminuria, and impaired glomerular filtration rate. It is possible that existing treatments for the management of diabetes, as metformin or SGLT2 inhibitors may also be useful in patients with prediabetes with evidence of functional and structural kidney damage. The purpose of this review is to summarize the evidence regarding the relationship between prediabetes(preDM) and the development of CKD. | eng |
| dc.format.mimetype | ||
| dc.identifier.citation | Fontalvo JR, Soler MJ, Arnedo RD, Navarro-Blackaller G, Medina-González R, Yánez TR, Cardona-Blanco M, Cabrales-Juan J, Uparrela-Gulfo I, Chávez-Iñiguez JS, Prediabetes and CKD: does a causal relationship exist? (2024), doi: https://doi.org/10.1016/j.nefro.2024.06.008 | eng |
| dc.identifier.doi | https://doi.org/doi:10.1016/j.nefro.2024.06.008 | |
| dc.identifier.issn | 19892284 (Online) | |
| dc.identifier.issn | 02116995 (Print) | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12442/14763 | |
| dc.identifier.url | https://www.sciencedirect.com/science/article/pii/S0211699524000626?via%3Dihub | |
| dc.language.iso | spa | |
| dc.publisher | Sociedad Española de Nefrología | spa |
| dc.rights | Attribution-NonCommercial-NoDerivs 3.0 United States | eng |
| dc.rights.accessrights | info:eu-repo/semantics/openAccess | |
| dc.rights.uri | http://creativecommons.org/licenses/by-nc-nd/3.0/us/ | |
| dc.source | Revista Nefrología | spa |
| dc.subject.keywords | Prediabetes | eng |
| dc.subject.keywords | Chronic kidney disease | eng |
| dc.subject.keywords | Albuminuria | eng |
| dc.subject.keywords | Hyperglycemia | eng |
| dc.title | Prediabetes and CKD: does a causal relationship exist? | eng |
| dc.type.driver | info:eu-repo/semantics/article | |
| dc.type.spa | Artículo científico | |
| dcterms.references | Echouffo-Tcheugui JB, Selvin E. Prediabetes and What It Means: The Epidemiological Evidence. Annu Rev Public Health. 2021 Apr 1;42:59–77. | eng |
| dcterms.references | Echouffo-Tcheugui JB, Narayan KM, Weisman D, Golden SH, Jaar BG. Association between prediabetes and risk of chronic kidney disease: a systematic review and meta-analysis. Diabet Med J Br Diabet Assoc. 2016 Dec;33(12):1615–24. | eng |
| dcterms.references | Cosic V, Jakab J, Pravecek MK, Miskic B. The Importance of Prediabetes Screening in the Prevention of Cardiovascular Disease. Med Arch Sarajevo Bosnia Herzeg. 2023 Apr;77(2):97–104. | eng |
| dcterms.references | Kim SH. A Nuanced Relationship Between Prediabetes and Chronic Kidney Disease. J Clin Endocrinol Metab. 2020 Apr 1;105(4):dgaa079. | eng |
| dcterms.references | Rett K, Gottwald-Hostalek U. Understanding prediabetes: definition, prevalence, burden and treatment options for an emerging disease. Curr Med Res Opin. 2019 Sep;35(9):1529–34. | eng |
| dcterms.references | American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2014 Jan;37 Suppl 1:S81-90. | eng |
| dcterms.references | World Health Organization, Federation ID. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia : report of a WHO/IDF consultation [Internet]. World Health Organization; 2006 [cited 2023 Mar 6]. Available from: https://apps.who.int/iris/handle/10665/43588 | eng |
| dcterms.references | Tabák AG, Herder C, Rathmann W, Brunner EJ, Kivimäki M. Prediabetes: a highrisk state for diabetes development. Lancet Lond Engl. 2012 Jun 16;379(9833):2279–90. | eng |
| dcterms.references | Zheng R, Xu Y, Li M, Gao Z, Wang G, Hou X, et al. Data-driven subgroups of prediabetes and the associations with outcomes in Chinese adults. Cell Rep Med. 2023 Mar 21;4(3):100958. | eng |
| dcterms.references | James C, Bullard KM, Rolka DB, Geiss LS, Williams DE, Cowie CC, et al. Implications of alternative definitions of prediabetes for prevalence in U.S. adults. Diabetes Care. 2011 Feb;34(2):387–91. | eng |
| dcterms.references | Gujral UP, Jagannathan R, He S, Huang M, Staimez LR, Wei J, et al. Association between varying cut-points of intermediate hyperglycemia and risk of mortality, cardiovascular events and chronic kidney disease: a systematic review and meta-analysis. BMJ Open Diabetes Res Care. 2021 Apr;9(1):e001776. | eng |
| dcterms.references | Cai X, Liu X, Sun L, He Y, Zheng S, Zhang Y, et al. Prediabetes and the risk of heart failure: A meta-analysis. Diabetes Obes Metab. 2021 Aug;23(8):1746–53. | eng |
| dcterms.references | Mai L, Wen W, Qiu M, Liu X, Sun L, Zheng H, et al. Association between prediabetes and adverse outcomes in heart failure. Diabetes Obes Metab. 2021 Nov;23(11):2476–83 | eng |
| dcterms.references | Jin J, Lu P. Association Between Prediabetes and Retinopathy: A Meta-Analysis. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2021 Dec;53(12):801–9. | eng |
| dcterms.references | Jin M, Yuan S, Wang B, Yi L, Wang C. Association Between Prediabetes and Erectile Dysfunction: A Meta-Analysis. Front Endocrinol. 2021;12:733434. | eng |
| dcterms.references | Cobo Marcos M, de la Espriella R, Gayán Ordás J, Llàcer P, Pomares A, Fort A, et al. Prevalence and clinical profile of kidney disease in patients with chronic heart failure. Insights from the Spanish cardiorenal registry. Rev Espanola Cardiol Engl Ed. 2023 May 20;S1885-5857(23)00140-8. | eng |
| dcterms.references | Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2020 Oct;98(4S):S1–115. | eng |
| dcterms.references | de Boer IH, Khunti K, Sadusky T, Tuttle KR, Neumiller JJ, Rhee CM, et al. Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO). Diabetes Care. 2022 Dec 1;45(12):3075–90. | eng |
| dcterms.references | Ali MK, Bullard KM, Saydah S, Imperatore G, Gregg EW. Cardiovascular and renal burdens of prediabetes in the USA: analysis of data from serial cross-sectional surveys, 1988-2014. Lancet Diabetes Endocrinol. 2018 May;6(5):392–403. | eng |
| dcterms.references | Huang Y, Cai X, Mai W, Li M, Hu Y. Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis. BMJ. 2016 Nov 23;355:i5953. | eng |
| dcterms.references | Tang O, Matsushita K, Coresh J, Sharrett AR, McEvoy JW, Windham BG, et al. Mortality Implications of Prediabetes and Diabetes in Older Adults. Diabetes Care. 2020 Feb;43(2):382–8. | eng |
| dcterms.references | Shilpasree AS, Patil VS, Revanasiddappa M, Patil VP, Ireshnavar D. Renal Dysfunction in Prediabetes: Confirmed by Glomerular Hyperfiltration and Albuminuria. J Lab Physicians. 2021 Sep;13(3):257–62. | eng |
| dcterms.references | Koye DN, Magliano DJ, Nelson RG, Pavkov ME. The Global Epidemiology of Diabetes and Kidney Disease. Adv Chronic Kidney Dis. 2018 Mar;25(2):121–32. | eng |
| dcterms.references | Lamprou S, Koletsos N, Mintziori G, Anyfanti P, Trakatelli C, Kotsis V, et al. Microvascular and Endothelial Dysfunction in Prediabetes. Life Basel Switz. 2023 Feb 25;13(3):644. | eng |
| dcterms.references | Daza-Arnedo R, Rico-Fontalvo JE, Pájaro-Galvis N, Leal-Martínez V, Abuabara- Franco E, Raad-Sarabia M, et al. Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review. Kidney Med. 2021 Dec;3(6):1065–73. | eng |
| dcterms.references | Neves JS, Correa S, Baeta Baptista R, Bigotte Vieira M, Waikar SS, Mc Causland FR. Association of Prediabetes With CKD Progression and Adverse Cardiovascular Outcomes: An Analysis of the CRIC Study. J Clin Endocrinol Metab. 2020 Apr 1;105(4):e1772-1780. | eng |
| dcterms.references | Alicic RZ, Rooney MT, Tuttle KR. Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin J Am Soc Nephrol CJASN. 2017 Dec 7;12(12):2032–45. | eng |
| dcterms.references | Rico-Fontalvo J, Aroca G, Cabrales J, Daza-Arnedo R, Yánez-Rodríguez T, Martínez-Ávila MC, et al. Molecular Mechanisms of Diabetic Kidney Disease. Int J Mol Sci. 2022 Aug 4;23(15):8668. | eng |
| dcterms.references | Whaley-Connell A, Sowers JR. Insulin Resistance in Kidney Disease: Is There a Distinct Role Separate from That of Diabetes or Obesity? Cardiorenal Med. 2017 Dec;8(1):41–9. | eng |
| dcterms.references | Wang J, Niratharakumar K, Gokhale K, Tahrani AA, Taverner T, Thomas GN, et al. Obesity Without Metabolic Abnormality and Incident CKD: A Population-Based British Cohort Study. Am J Kidney Dis Off J Natl Kidney Found. 2022 Jan;79(1):24-35.e1. | eng |
| dcterms.references | Fritz J, Brozek W, Concin H, Nagel G, Kerschbaum J, Lhotta K, et al. The Triglyceride-Glucose Index and Obesity-Related Risk of End-Stage Kidney Disease in Austrian Adults. JAMA Netw Open. 2021 Mar 1;4(3):e212612. | eng |
| dcterms.references | Kawata I, Koshi T, Hirabayashi K, Koike H, Sato Y, Yamashita K, et al. Prediabetes defined by the International Expert Committee as a risk for development of glomerular hyperfiltration. Acta Diabetol. 2019 May;56(5):525–9. | eng |
| dcterms.references | Lay AC, Coward RJM. The Evolving Importance of Insulin Signaling in Podocyte Health and Disease. Front Endocrinol. 2018;9:693. | eng |
| dcterms.references | Pina AF, Borges DO, Meneses MJ, Branco P, Birne R, Vilasi A, et al. Insulin: Trigger and Target of Renal Functions. Front Cell Dev Biol. 2020;8:519. | eng |
| dcterms.references | Melsom T, Schei J, Stefansson VTN, Solbu MD, Jenssen TG, Mathisen UD, et al. Prediabetes and Risk of Glomerular Hyperfiltration and Albuminuria in the General Nondiabetic Population: A Prospective Cohort Study. Am J Kidney Dis Off J Natl Kidney Found. 2016 Jun;67(6):841–50. | eng |
| dcterms.references | Okada R, Wakai K, Naito M, Morita E, Kawai S, Yin G, et al. Renal hyperfiltration in prediabetes confirmed by fasting plasma glucose and hemoglobin A1c. Ren Fail. 2012;34(9):1084–90. | eng |
| dcterms.references | Reboldi G, Verdecchia P, Fiorucci G, Beilin LJ, Eguchi K, Imai Y, et al. Glomerular hyperfiltration is a predictor of adverse cardiovascular outcomes. Kidney Int. 2018 Jan;93(1):195–203. | eng |
| dcterms.references | Kanbay M, Ertuglu LA, Afsar B, Ozdogan E, Kucuksumer ZS, Ortiz A, et al. Renal hyperfiltration defined by high estimated glomerular filtration rate: A risk factor for cardiovascular disease and mortality. Diabetes Obes Metab. 2019 Nov;21(11):2368–83. | eng |
| dcterms.references | Gaspari F, Ruggenenti P, Porrini E, Motterlini N, Cannata A, Carrara F, et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int. 2013 Jul;84(1):164–73. | eng |
| dcterms.references | Markus MRP, Ittermann T, Baumeister SE, Huth C, Thorand B, Herder C, et al. Prediabetes is associated with microalbuminuria, reduced kidney function and chronic kidney disease in the general population: The KORA (Cooperative Health Research in the Augsburg Region) F4-Study. Nutr Metab Cardiovasc Dis NMCD. 2018 Mar;28(3):234–42. | eng |
| dcterms.references | Suzuki Y, Kaneko H, Okada A, Itoh H, Fujiu K, Michihata N, et al. Impact of Glucose Tolerance and Its Change on Incident Proteinuria: Analysis of a Nationwide Population-Based Dataset. Am J Nephrol. 2022;53(4):307–15. | eng |
| dcterms.references | Furukawa M, Onoue T, Kato K, Wada T, Shinohara Y, Kinoshita F, et al. Prediabetes is associated with proteinuria development but not with glomerular filtration rate decline: A longitudinal observational study. Diabet Med J Br Diabet Assoc. 2021 Aug;38(8):e14607. | eng |
| dcterms.references | Plantinga LC, Crews DC, Coresh J, Miller ER, Saran R, Yee J, et al. Prevalence of chronic kidney disease in US adults with undiagnosed diabetes or prediabetes. Clin J Am Soc Nephrol CJASN. 2010 Apr;5(4):673–82. | eng |
| dcterms.references | Razeghi E, Heydarian P, Heydari M. The frequency of prediabetes and contributing factors in patients with chronic kidney disease. Rev Diabet Stud RDS. 2011;8(2):276–81. | eng |
| dcterms.references | Vanholder R, Gryp T, Glorieux G. Urea and chronic kidney disease: the comeback of the century? (in uraemia research). Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc. 2018 Jan 1;33(1):4–12. | eng |
| dcterms.references | do Nascimento GVR, Balbi AL, Ponce D, Abrão JMG. Early initiation of dialysis: mortality and renal function recovery in acute kidney injury patients. J Bras Nefrol Orgao Of Soc Bras E Lat-Am Nefrol. 2012;34(4):337–42. | eng |
| dcterms.references | Lin L, Lu J, Chen L, Mu Y, Ye Z, Liu C, et al. Glycemic status and chronic kidney disease in Chinese adults: Findings from the REACTION study. J Diabetes. 2017 Sep;9(9):837–45. | eng |
| dcterms.references | Schlesinger S, Neuenschwander M, Barbaresko J, Lang A, Maalmi H, Rathmann W, et al. Prediabetes and risk of mortality, diabetes-related complications and comorbidities: umbrella review of meta-analyses of prospective studies. Diabetologia. 2022 Feb;65(2):275–85. | eng |
| dcterms.references | Trevisani F, Di Marco F, Capitanio U, Larcher A, Bettiga A, Dosio F, et al. Renal Function Assessment Gap in Clinical Practice: An Awkward Truth. Kidney Blood Press Res. 2020;45(2):166–79. | eng |
| dcterms.references | Huang J, Huth C, Covic M, Troll M, Adam J, Zukunft S, et al. Machine Learning Approaches Reveal Metabolic Signatures of Incident Chronic Kidney Disease in Individuals With Prediabetes and Type 2 Diabetes. Diabetes. 2020 Dec;69(12):2756–65. | eng |
| dcterms.references | Herman WH, Hoerger TJ, Brandle M, Hicks K, Sorensen S, Zhang P, et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med. 2005 Mar 1;142(5):323–32. | eng |
| dcterms.references | Glechner A, Keuchel L, Affengruber L, Titscher V, Sommer I, Matyas N, et al. Effects of lifestyle changes on adults with prediabetes: A systematic review and metaanalysis. Prim Care Diabetes. 2018 Oct;12(5):393–408. | eng |
| dcterms.references | Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Program (DPP): description of lifestyle intervention. Diabetes Care. 2002 Dec;25(12):2165–71. | eng |
| dcterms.references | Zucatti KP, Teixeira PP, Wayerbacher LF, Piccoli GF, Correia PE, Fonseca NKO, et al. Long-term Effect of Lifestyle Interventions on the Cardiovascular and All-Cause Mortality of Subjects With Prediabetes and Type 2 Diabetes: A Systematic Review and Meta-analysis. Diabetes Care. 2022 Nov 1;45(11):2787–95. | eng |
| dcterms.references | Fritsche A, Wagner R, Heni M, Kantartzis K, Machann J, Schick F, et al. Different Effects of Lifestyle Intervention in High- and Low-Risk Prediabetes: Results of the Randomized Controlled Prediabetes Lifestyle Intervention Study (PLIS). Diabetes. 2021 Dec;70(12):2785–95. | eng |
| dcterms.references | Hostalek U, Gwilt M, Hildemann S. Therapeutic Use of Metformin in Prediabetes and Diabetes Prevention. Drugs. 2015 Jul;75(10):1071–94. | eng |
| dcterms.references | Warrilow A, Somerset S, Pumpa K, Fleet R. Metformin use in prediabetes: is earlier intervention better? Acta Diabetol. 2020 Nov;57(11):1359–66. | eng |
| dcterms.references | Luo Y, Wang H, Zhou X, Chang C, Chen W, Guo X, et al. A Randomized Controlled Clinical Trial of Lifestyle Intervention and Pioglitazone for Normalization of Glucose Status in Chinese with Prediabetes. J Diabetes Res. 2022;2022:2971382. | eng |
| dcterms.references | Zhou Y, Huang Y, Ji X, Wang X, Shen L, Wang Y. Pioglitazone for the Primary and Secondary Prevention of Cardiovascular and Renal Outcomes in Patients with or at High Risk of Type 2 Diabetes Mellitus: A Meta-Analysis. J Clin Endocrinol Metab. 2020 May 1;105(5):dgz252. | eng |
| dcterms.references | Galaviz KI, Weber MB, Suvada K, Gujral UP, Wei J, Merchant R, et al. Interventions for Reversing Prediabetes: A Systematic Review and Meta-Analysis. Am J Prev Med. 2022 Apr;62(4):614–25. | eng |
| dcterms.references | American Diabetes Association. 5. Prevention or Delay of Type 2 Diabetes: Standards of Medical Care in Diabetes-2018. Diabetes Care. 2018 Jan;41(Suppl 1):S51–4. | eng |
| dcterms.references | Diabetes Prevention Program Research Group, Knowler WC, Fowler SE, Hamman RF, Christophi CA, Hoffman HJ, et al. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet Lond Engl. 2009 Nov 14;374(9702):1677–86. | eng |
| dcterms.references | Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou FF, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020 Oct 8;383(15):1436–46. | eng |
| dcterms.references | Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023 Jan 12;388(2):117–27. | eng |
| dcterms.references | Prandi FR, Barone L, Lecis D, Belli M, Sergi D, Milite M, et al. Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors. Biomolecules. 2022 Sep 22;12(10):1349. | eng |
| dcterms.references | Jaikumkao K, Pongchaidecha A, Chueakula N, Thongnak LO, Wanchai K, Chatsudthipong V, et al. Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic rats. Diabetes Obes Metab. 2018 Nov;20(11):2617–26. | eng |
| dcterms.references | PERSSON F, ROSSING P, VART P, CHERTOW GM, HOU FF, MCMURRAY JJ, et al. 317-OR: Efficacy and Safety of Dapagliflozin by Glycemic Status in the DAPA-CKD Trial. Diabetes. 2021 Jun 1;70(Supplement_1):317-OR. | eng |
| dcterms.references | Persson F, Rossing P, Vart P, Chertow GM, Hou FF, Jongs N, et al. Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial. Diabetes Care. 2021 Aug;44(8): 1894-7 | eng |
| dcterms.references | Y, Duru OK, Tuttle KR, Fukuma S, Taura D, Harada N, et al. Sodium- Glucose Cotransporter 2 Inhibitors and New-onset Type 2 Diabetes in Adults With Prediabetes: Systematic Review and Meta-analysis of Randomized Controlled Trials. J Clin Endocrinol Metab. 2022 Dec 17;108(1):87-104 | eng |
| dcterms.references | Merovci A, Solis-Herrera C, Daniele G, Eldor R, Fiorentino TV, Tripathy D, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014 Feb;124(2):509–14. | eng |
| dcterms.references | Al Jorobi H, Daniele G, Adams J, Cersosimo E, Solis-Herrera C, Triplitt C, et al. Empagliflozin Treatment Is Associated With Improved β-Cell Function in Type 2 Diabetes Mellitus. J Clin Endocrinol Metab. 2018 Apr 1;103(4):1402–7. | eng |
| dcterms.references | Merovci A, Mari A, Solis-Herrera C, Xiong J, Daniele G, Chavez-Velazquez A, et al. Dapagliflozin lowers plasma glucose concentration and improves β-cell function. J Clin Endocrinol Metab. 2015 May;100(5):1927–32. | eng |
| dcterms.references | Rico-Fontalvo J, Daza-Arnedo R, Raad-Sarabia M, Pájaro-Galvis N, Uparella-Gulfo I, Porto-Corbacho D, et al. Metformina y su rol en la enfermedad renal: estado del arte. Rev Nefrol Latinoam. 2022 Dec 19;19(2):129–36. | eng |
| dcterms.references | 2. Classification and Diagnosis of Diabetes: Standards of Care in Diabetes—2023 | Diabetes Care | American Diabetes Association [Internet]. [cited 2023 Mar 1]. Available from: https://diabetesjournals.org/care/article/46/Supplement_1/S19/148056/2- Classification-and-Diagnosis-of-Diabetes | eng |
| oaire.version | info:eu-repo/semantics/acceptedVersion |